Economic Comparison of Empirical Versus Diagonstic-Driven Strategies for Immunocompromised Patients with Suspected Fungal Infection Results from a Chinese Payer Perspective.

Qin, L; Chen, Y; Zhao, W; Mao, N; Charbonneau, C; Gao, X

Qin, L; Chen, Y; Zhao, W; Mao, N; Charbonneau, C; Gao, X.

Afiliación

Qin L; Pharmerit International, Bethesda, MD, USA.
Chen Y; Pfizer Investment Co. Ltd., Beijing, China.
Zhao W; Shanghai Rui Jin Hospital, Shanghai, China.
Mao N; China Pharmaceutical University, Nanjing, China.
Charbonneau C; Pfizer Inc., Paris, France.
Gao X; Pharmerit International, Bethesda, MD, USA.

Value Health ; 17(7): A670, 2014 Nov.

Article en En | MEDLINE | ID: mdl-27202457

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google